Urology · Phoenix, AZ
NPI
1760487367
Since 2005
Specialty
Urology
Code 208800000X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
14231 N 7th St Ste 3a
Phoenix, AZ, 85022
Phone (844) 667-7376
Groups this clinician bills Medicare through
Medicare paid, 2024
$304K
8,339 services
Medicare patients, 2024
605
Average age 78
Drug cost, 2024
$235K
1,521 prescriptions
Company payments, 2025
$564
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mitchell C Kaye was code J9030 (bcg live intravesical instillation, 1 mg), 2,770 times for 12 patients. In total Mitchell C Kaye billed 8,339 services in 87 codes, and Medicare paid $304K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9030 Bcg live intravesical instillation, 1 mg | Office | 2,770 | 12 | $2.29 | $6,347 |
| 81000 Clinical Chemistry | Office | 1,207 | 556 | $3.94 | $4,752 |
| 99214 Office E&M - Established | Office | 871 | 411 | $92.72 | $81K |
| 99213 Office E&M - Established | Office | 454 | 274 | $65.65 | $30K |
| 52000 Cystourethroscopy | Office | 178 | 140 | $180.96 | $32K |
| 51798 Ultrasound - Nonspecific | Office | 130 | 100 | $8.48 | $1,102 |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 112 | 16 | $142.18 | $16K |
| 99204 Office E&M - New | Office | 93 | 93 | $123.29 | $11K |
| 51720 Chemotherapy Administration | Office | 60 | 12 | $67.98 | $4,079 |
| 51705 Other Organ Systems | Office | 55 | 12 | $68.49 | $3,767 |
| 88313 Surgical Pathology Examination | Office | 47 | 41 | $49.82 | $2,341 |
| 88112 Surgical Pathology Examination | Office | 47 | 41 | $29.70 | $1,396 |
| 52442 Cystourethroscopy | Facility | 39 | 11 | $38.18 | $1,489 |
| 88342 Immunohistochemistry | Office | 38 | 15 | $52.57 | $1,998 |
| 51702 Other Organ Systems | Office | 31 | 12 | $47.79 | $1,481 |
By year: 2022 $348K for 14,586 services; 2023 $358K for 18,417 services; 2024 $304K for 8,339 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81000 Clinical Chemistry | 1,207 | 556 | $3.94 | $4,752 |
| 88112 Surgical Pathology Examination | 47 | 41 | $29.70 | $1,396 |
| 88313 Surgical Pathology Examination | 47 | 41 | $49.82 | $2,341 |
| 88342 Immunohistochemistry | 38 | 15 | $52.57 | $1,998 |
| 88120 Surgical Pathology Examination | 30 | 24 | $395.00 | $12K |
| 88344 Immunohistochemistry | 17 | 16 | $103.05 | $1,752 |
| G0416 Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 16 | 16 | $113.74 | $1,820 |
Medicare prescription drug claims, 2024
In 2024, the drug Mitchell C Kaye prescribed most often to Medicare patients was Tamsulosin Hcl, with 435 prescriptions and refills. In total Mitchell C Kaye wrote 1,521 Medicare prescriptions that cost $235K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 435 | 1,173 | 153 | $6,493 |
| Finasteride Generic | 208 | 590 | 63 | $3,148 |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 127 | 129 | 72 | $2,128 |
| Myrbetriq Mirabegron | 101 | 221 | 27 | $98K |
| Tolterodine Tartrate Er Tolterodine Tartrate | 85 | 179 | 25 | $4,056 |
| Methenamine Hippurate Generic | 76 | 144 | 23 | $5,721 |
| Cephalexin Generic | 60 | 72 | 45 | $358 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 59 | 59 | 47 | $839 |
| Ciprofloxacin Hcl Generic | 41 | 42 | 38 | $356 |
| Levofloxacin Generic | 35 | 35 | 25 | $85.03 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 30 | 62 | Under 11 | $405 |
| Alfuzosin Hcl Er Alfuzosin Hcl | 27 | 63 | Under 11 | $409 |
| Bicalutamide Generic | 25 | 53 | 11 | $532 |
| Testosterone Generic | 22 | 27 | Under 11 | $1,855 |
| Potassium Citrate Er Potassium Citrate | 17 | 49 | Under 11 | $1,181 |
Brand drugs: - claims; generic drugs: 1,350 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mitchell C Kaye $564 ($564 in general payments such as food, travel and fees) from 7 companies. The largest payer was Coloplast Corp with $232.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.